E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Neutropenic and febrile patients with hematological or solid tumors, who are at high risk for gram-positive bacterial infection. |
|
E.1.1.1 | Medical condition in easily understood language |
Patients with neutropenic (low white blood cells) fever, who are at high risk of bacterial infection induced by cancer treatment. |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Bacterial Infections and Mycoses [C01] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 17.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10060945 |
E.1.2 | Term | Bacterial infection |
E.1.2 | System Organ Class | 10021881 - Infections and infestations |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate whether or not the use of Teicoplanin during initial empirical antibiotic treatment of febrile neutropenic patients at high risk for gram-positive infection was at least equivalent to Vancomycin in terms of fever remission or eradication of isolated gram-positive bacteria. |
|
E.2.2 | Secondary objectives of the trial |
To evaluate whether or not there was any difference between the two regimens in terms of side effect profiles. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. In neutropenic and febrile patients with hematological or solid tumors
• Absolute neutrophil counts (ANC) of less than or equal to 500/mm3 in peripheral blood was considered as neutropenia Patients with absolute neutrophil counts between 500 and 1000/mm3 which was expected to fall below 500/mm3 in the next 24 hours due to chemotherapy were also be considered as neutropenic.
2. In order for a patient to be considered febrile, body temperature measured by oral or axillary method should be over 38.3 ºC once or over 38.0 ºC twice in at least half an hour intervals in a 12 hour period.
3. Patients were included in the study in their first fever attack of febrile neutropenic episodes. Therefore patients who were febrile for at least 3 days after the empirical treatment of previous febrile attack have been included in the study. Each patient was only included once in this study. |
|
E.4 | Principal exclusion criteria |
1. Patients or legal representatives who did not provide informed consent to participate in the study
2. Pregnant or lactating women.
3. Patients previously enrolled in this study
4. Patients with neutropenia due to reasons other than cancer chemotherapy (i.e. aplastic anemia)
5. Patients in blastic phase of chronic myeloblastic leukemia
6. Patients with known HIV infection
7. Patients with central venous catheter in which prophylactic “antibiotic lock” was used
8. Patients with possible infections due to anaerobic bacteria, fungus, mycoplasma, virus, protozoa or rickettsia.
9. Patients requiring initiation of concomitant anti-anaerobic, anti-viral or anti-fungal medication at the beginning of treatment
10. More than one dose of antimicrobial medication use 3 days prior to the use of study medications (quinolone and/or trimethoprim/sulphamethoxazole use due to bone marrow transplantation did not preclude to participate in the study).
11. Patients receiving antifungal fluconazole and itraconazole for treatment purposes (Patients receiving these agents for prophylactic purposes were included in the study).
12. Patients with a life expectancy of less than 48 hours.
13. Patients with lung infiltration
14. Patients with necrotizing colitis, liver abscess or perirectal infections
15. Patients with any known allergy to beta-lactam antibiotics, aminoglycosides, Vancomycin or Teicoplanin.
16. Patients with severe renal (serum creatinine level of >2 mg/dL or creatinine clearance of <40 ml/min) or hepatic failure (serum transaminase level of 4 times normal or higher).
17. Patients with alcohol or drug dependency or personality disorder or other psychological disorder that might render adherence to protocol requirements or influence the process of consent.
18. Patients who, within one month before this study, have used any medications for experimental purposes in some other study. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Number of subjects according to treatment response. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
5 days after the completion of treatment maximum of 26 days. |
|
E.5.2 | Secondary end point(s) |
Percentage of subjects with new infection.
Percentage of subjects with protocol treatment modification or alteration.
Survival at 30 days. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
At the end of treatment maximum 21 days.
We propose 30 Days. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
Will this trial be conducted at a single site globally?
| No |
E.8.4 | Will this trial be conducted at multiple sites globally? | Yes |
E.8.6 Trial involving sites outside the EEA |
E.8.6.2 | Trial being conducted completely outside of the EEA | Yes |
E.8.6.3 | Specify the countries outside of the EEA in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 8 |